-
公开(公告)号：US20210060160A1
公开(公告)日：2021-03-04
申请号：US17020108
申请日：2020-09-14
Applicant: UCB PHARMA, S.A.
Inventor： Martyn K. Robinson
IPC: A61K39/395 , A61K33/42 , A61K45/06 , C07K16/22
Abstract: The invention relates to the treatment of bone disorders. In particular, the invention is directed to the use of a dosing holiday to help overcome the resistance to anti-sclerostin antibodies which develops over time when a plurality of doses of antibody are given to a subject. By giving the subject to be treated such a dosing holiday, the subject may subsequently display an increased response to a subsequent dose of the anti-sclerostin antibody. The subject may be given multiple cycles of a batch of at least two doses of anti-sclerostin antibody and a dosing holiday. In some instances, the subject may be monitored to help determine when to give the dosing holiday. Further, the subject may be given a different treatment for the bone disorder during the dosing holiday from the anti-sclerostin antibody.
-
公开(公告)号：US10799583B2
公开(公告)日：2020-10-13
申请号：US15887299
申请日：2018-02-02
Applicant: UCB PHARMA, S.A.
Inventor： Martyn K. Robinson
Abstract: The invention relates to the treatment of bone disorders. In particular, the invention is directed to the use of a dosing holiday to help overcome the resistance to anti-sclerostin antibodies which develops over time when a plurality of doses of antibody are given to a subject. By giving the subject to be treated such a dosing holiday, the subject may subsequently display an increased response to a subsequent dose of the anti-sclerostin antibody. The subject may be given multiple cycles of a batch of at least two doses of anti-sclerostin antibody and a dosing holiday. In some instances, the subject may be monitored to help determine when to give the dosing holiday. Further, the subject may be given a different treatment for the bone disorder during the dosing holiday from the anti-sclerostin antibody.
-
公开(公告)号：US10189897B2
公开(公告)日：2019-01-29
申请号：US14977688
申请日：2015-12-22
Applicant: UCB PHARMA, S.A.
Abstract: The present invention relates to a process for the purification of an antibody fragment from a periplasmic cell extract comprising a first cation exchange chromatography step and a second anion exchange chromatography step.
-
公开(公告)号：US10017575B2
公开(公告)日：2018-07-10
申请号：US15242135
申请日：2016-08-19
Applicant: UCB Pharma S.A.
Inventor： Alastair David Griffiths Lawson , Andrew Malcolm Nesbitt , Andrew George Popplewell , Stevan Graham Shaw , Diana Shpektor , Yi Zhang
IPC: C07K16/18 , C07K16/28 , A61K39/395 , A61K45/06 , C07K14/705 , A61K39/00
CPC classification number: C07K16/2878 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K14/70578 , C07K2317/24 , C07K2317/33 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
-
公开(公告)号：US20180169235A1
公开(公告)日：2018-06-21
申请号：US15887299
申请日：2018-02-02
Applicant: UCB PHARMA, S.A.
Inventor： Martyn K. Robinson
Abstract: The invention relates to the treatment of bone disorders. In particular, the invention is directed to the use of a dosing holiday to help overcome the resistance to anti-sclerostin antibodies which develops over time when a plurality of doses of antibody are given to a subject. By giving the subject to be treated such a dosing holiday, the subject may subsequently display an increased response to a subsequent dose of the anti-sclerostin antibody. The subject may be given multiple cycles of a batch of at least two doses of anti-sclerostin antibody and a dosing holiday. In some instances, the subject may be monitored to help determine when to give the dosing holiday. Further, the subject may be given a different treatment for the bone disorder during the dosing holiday from the anti-sclerostin antibody.
-
Patent Agency Ranking
公开(公告)号：US09791462B2
公开(公告)日：2017-10-17
申请号：US14626274
申请日：2015-02-19
Applicant: UCB PHARMA S.A.
Inventor： Mary E. Brunkow , David J. Galas , Brian Kovacevich , John T. Mulligan , Bryan W. Paeper , Jeffrey Van Ness , David G. Winkler
IPC: G01N33/68 , G01N33/84 , C07K14/475 , A61K38/18 , A61K45/06 , G01N33/74 , C07K14/51 , C07K16/18 , C07K16/22 , C12Q1/68 , A61K39/395 , A61K48/00
CPC classification number: G01N33/74 , A01K2217/05 , A01K2217/075 , A61K38/18 , A61K39/3955 , A61K45/06 , A61K48/00 , C07K14/475 , C07K14/51 , C07K16/18 , C07K16/22 , C07K2317/11 , C07K2317/23 , C07K2319/00 , C12N2799/021 , C12Q1/6883 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172 , G01N33/6872 , G01N33/84 , G01N2333/47 , G01N2333/495 , G01N2333/51 , G01N2500/02 , G01N2500/20
Abstract: A novel class or family of TGF-β binding proteins is disclosed. Also disclosed are assays for selecting molecules for increasing bone mineralization and methods for utilizing such molecules.
-
公开(公告)号：US09751930B2
公开(公告)日：2017-09-05
申请号：US13812350
申请日：2011-07-27
Applicant: Gavin Barry Wild
Inventor： Gavin Barry Wild
CPC classification number: C07K16/00 , C07K1/30 , C07K16/241 , C07K2317/14 , C07K2317/55 , C12N9/90 , C12P21/00
Abstract: The present invention provides method for purifying a recombinant protein from a gram-negative bacterial host cell sample or extract thereof wherein said host cell expresses a recombinant protein and a recombinant disulphide isomerase DsbC; comprising: a. adjusting the pH of the host cell sample or extract thereof to a pH of 5 or less to precipitate the recombinant disulphide isomerase; and b. separating precipitated recombinant disulphide isomerase DsbC from the recombinant protein to produce a recombinant protein sample.
-
公开(公告)号：US09725516B2
公开(公告)日：2017-08-08
申请号：US14131994
申请日：2012-07-13
Applicant: Mark Ellis , David Paul Humphreys
Inventor： Mark Ellis , David Paul Humphreys
CPC classification number: C07K16/2875 , C07K2317/14 , C07K2317/55 , C12N9/90
Abstract: The present invention provides a recombinant gram-negative bacterial cell comprising an expression vector comprising a recombinant polynucleotide encoding DsbC and one or more polynucleotides encoding an antibody or an antigen-binding fragment thereof specifically binding to CD154.
-
公开(公告)号：US09657095B2
公开(公告)日：2017-05-23
申请号：US14662538
申请日：2015-03-19
Applicant: UCB PHARMA S.A.
Inventor： David G. Winkler , Jiye Shi , John Latham
IPC: A61K39/00 , A61K39/395 , C07K16/00 , C07K16/18 , C07K16/22 , C12N1/21 , C12N5/10 , C12N5/12 , C12N15/11 , C12N15/13 , C12N15/63 , C07K14/51 , A61K47/48 , C07K14/475 , G01N33/68
CPC classification number: C07K16/22 , A61K47/643 , A61K47/646 , C07K14/475 , C07K14/51 , C07K16/18 , C07K2317/76 , G01N33/6854 , G01N2333/4704
Abstract: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.
-
公开(公告)号：US09630948B2
公开(公告)日：2017-04-25
申请号：US14909246
申请日：2014-07-28
Applicant: UCB Pharma, S.A.
Inventor： Florian Montel , Eric Jnoff
IPC: A01N43/64 , A61K31/41 , C07D249/08 , C07D403/06
CPC classification number: C07D403/06
Abstract: The invention relates to 2-oxo-1-pyrrolidinyl triazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals for enhancing the cognitive function or to counteract cognitive decline.
-
-
-
-
-
-
-
-
-
Search Results
330
records
(took 0.047 seconds)
